Article
Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients.
The pharmacogenomics journal - 1 Feb 2021
Hannachi Ibtissem, Chadli Zohra, Kerkeni Emna, Kolsi Abdessalem, Hammouda Mouna, Chaabane Amel, Ben Fredj Nadia, Touitou Yvan, Boughattas Naceur A, Aouam Karim
Abstract excerpt
Tacrolimus is characterized by a highly variable pharmacokinetics (PK) and a small therapeutic window. It is metabolized specifically by the CYP3A isoenzymes. This study aimed to determine, in kidney transplant patients, the influence of different genotypic clusters involving these SNPs CYP3A4*1B, CYP3A4*22, and CYP3A5*3 on Tacrolimus bioavailability during the first (PTP1) and the second (PTP2) posttransplant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
